×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Japanese drugmaker Eisai on Thursday said the distribution of its Alzheimer's drug Leqembi in the United States has proceeded slower than it...
2 months ago
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Fierce Pharma
Eisai, Biogen's injectable Leqembi delayed as FDA asks for more data ... What analysts viewed as a potential “inflection point” for Eisai and...
1 month ago
Teaming up with Eisai to help fight cancer
Merck.com
“Combining Merck's leadership in immuno-oncology with Eisai's strengths in small molecules allows us to advance a combination approach that has...
4 weeks ago
Medicare expects spending spike for Biogen, Eisai Alzheimer's drug- STAT
STAT
Medicare expects its spending on the Alzheimer's drug Leqembi to reach $3.5 billion in 2025, far exceeding Wall Street analyst expectations.
3 weeks ago
BioArctic partners with Eisai on Alzheimer's treatment
Pharmaceutical Technology
Swedish research-based biopharma company BioArctic has signed an agreement with Eisai for a research evaluation focusing on BAN2802,...
2 weeks ago
Eisai seeks FDA approval of Leqembi IV maintenance dosing
Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer's disease.
1 month ago
Focus On - Eisai, Dicerna Pharmaceuticals, Neurological
The Pharma Letter
The week in pharma: action, reaction and insight - week to November 19 2021. 21-11-2021. News of note last week included US Pharma giant Merck & Co...
1 day ago
Eisai to drop up to $15M on C2N Diagnostics to boost the reach of Alzheimer's disease blood tests
Fierce Biotech
Eisai previously joined C2N on a project to assemble real-world evidence that supports the use of blood tests in people with cognitive...
2 months ago
Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb) | Biogen
Biogen
Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb) ... Eisai will host its annual information meeting which will...
2 months ago
Eisai to Likely Miss Patient Goal for Leqembi by End of March 2024
BioSpace
Thanks to a rough launch of its Biogen-partnered Alzheimer's disease treatment, Eisai will likely miss its target of treating 10000 patients...
3 months ago